Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2010138496 |
Title |
Iap Inhibitors. |
Abstract |
The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. |
Applicant(s) |
Tetralogic Pharmaceuticals Corp |
Representative Drug(s) |
D03PTG |
Drug Info
|
KD < 100 nM |
Click to Show More |
[1] |
2
|
D0CV9K
|
Drug Info
|
KD < 100 nM
|
[1] |
Patent ID |
WO2010033531 |
Title |
Iap Inhibitors. |
Abstract |
The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. |
Applicant(s) |
Tetralogic Pharmaceuticals Corp |
Representative Drug(s) |
D0M3BY |
Drug Info
|
KD < 100 nM |
Click to Show More |
[1] |
2
|
D0MH4B
|
Drug Info
|
KD < 100 nM
|
[1] |
Patent ID |
WO2014060770 |
Title |
Bicyclic Heterocycle Compounds and Their Uses In Therapy. |
Abstract |
The invention relates to new bicyclic heterocycle compounds of formula (I):,to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. |
Applicant(s) |
Astex Therapeutics Limited |
Representative Drug(s) |
D0ID3R |
Drug Info
|
98% inhibition = 12 nM |
[1] |
Patent ID |
WO2014060768 |
Title |
Bicyclic Heterocycle Compounds and Their Uses In Therapy. |
Abstract |
The invention relates to new bicyclic heterocycle compounds of formula (I): wherein R1 is seected from specific pyrazolyl, imidazolyl, pridinyl and triazolyl groups. The invention also realtes to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. |
Applicant(s) |
ASTEX THERAPEUTICS LIMITED |
Representative Drug(s) |
D02ZHC |
Drug Info
|
98% inhibition = 12 nM |
[1] |
Patent ID |
WO2014060767 |
Title |
Bicyclic Heterocycle Compounds and Their Uses In Therapy. |
Abstract |
The invention relates to new bicyclic heterocycle compounds of formula (I): (Formula (I)), pharmaceutical compositions comprising said compounds and to use of said compounds in the treatment of diseases, e.g. cancer. |
Applicant(s) |
ASTEX THERAPEUTICS LIMITED |
Representative Drug(s) |
D02UOD |
Drug Info
|
100% inhibition = 12 nM |
[1] |
Patent ID |
WO2014031487 |
Title |
Bivalent Inhibitors of Iap Proteins and Therapeutic Methods Using The Same. |
Abstract |
Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed. |
Applicant(s) |
THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
Representative Drug(s) |
D0YN1X |
Drug Info
|
IC50 < 100 nM |
[1] |
Patent ID |
WO2012080271 |
Title |
Dimeric Iap Inhibitors. |
Abstract |
The present invention provides compounds of formula M-L-M' (where M and M' are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. (I). |
Applicant(s) |
NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang |
Representative Drug(s) |
D0AC8H |
Drug Info
|
EC50 = 1.2 nM |
[1] |
Patent ID |
WO2012080260 |
Title |
Dimeric Iap Inhibitors. |
Abstract |
The present invention provides compounds of formula M-L-M' (where M and M' are each independently a monomeric moiety of Formula (I), (II), (III) or (IV) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. |
Applicant(s) |
NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang |
Representative Drug(s) |
D07FRU |
Drug Info
|
EC50 = 0.9 nM |
[1] |
Patent ID |
WO2011104266 |
Title |
Dimeric Iap Inhibitors. |
Abstract |
The present invention provides compounds of formula M-L-M' (where M and M' are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. |
Applicant(s) |
NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang PALERMO, Mark G. |
Representative Drug(s) |
D0GF3P |
Drug Info
|
EC50 = 0.6 nM |
[1] |
Patent ID |
WO2011098904 |
Title |
Iap Bir Domain Binding Compounds. |
Abstract |
A compound of Formula 1 : (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods. |
Applicant(s) |
Pharmascience Inc |
Representative Drug(s) |
D0R3YM |
Drug Info
|
Ki < 25 nM |
[1] |
Patent ID |
WO2011082285 |
Title |
Ligand-Directed Covalent Modification of Protein. |
Abstract |
The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use. |
Applicant(s) |
Avila Therapeutics, Inc |
Representative Drug(s) |
D09VAX |
Drug Info
|
Ki < 1000 nM |
[1] |
Patent ID |
WO2011068926 |
Title |
Iap Inhibitors. |
Abstract |
The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. |
Applicant(s) |
Tetralogic Pharmaceuticals Corp |
Representative Drug(s) |
D03VPP |
Drug Info
|
KD < 100 nM |
[1] |
Patent ID |
WO2011050068 |
Title |
Bivalent Diazo Bicyclic Smac Mimetics and The Uses Thereof. |
Abstract |
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The invention also relates to the use of bivalent diazo bicyclic Smac mimetics for inducing or sensitizing cells to the induction of apoptotic cell death. Thus, compounds of the invention are useful in the treatment, amelioration, or prevention of hyperproliferative diseases such as cancer. |
Applicant(s) |
The Regents of the University of Michigan |
Representative Drug(s) |
D0HY5Q |
Drug Info
|
IC50 < 10 nM |
[1] |
Patent ID |
WO2011016576 |
Title |
Alanine Derivatives As Inhibitors of Apoptosis Proteins. |
Abstract |
The present invention provides a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention shows a strong IAP antagonistic activity. |
Applicant(s) |
TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Representative Drug(s) |
D08XOV |
Drug Info
|
100.50% inhibition = 3000 nM |
[1] |
Patent ID |
WO2010142994 |
Title |
2, 3-Dihydro-1H-Indene Compounds and Their Use To Treat Cancer. |
Abstract |
Provided herein are 2,3-dihydro-1H-indene compounds, methods for making the compounds, pharmaceutical compositions containing the compounds. The described compounds inhibit IAP proteins and can be used to treat various cancers. |
Applicant(s) |
Astrazeneca Ab |
Representative Drug(s) |
D0B6KC |
Drug Info
|
IC50 = 15 nM |
[1] |
Patent ID |
WO2010138666 |
Title |
Iap Inhibitors. |
Abstract |
The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. |
Applicant(s) |
Tetralogic Pharmaceuticals Corp |
Representative Drug(s) |
D03DQW |
Drug Info
|
KD < 100 nM |
[1] |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20130225567 |
Title |
International Gmbh. 5-Alkynyl Pyridine. |
Representative Drug(s) |
D0O8ZD |
Drug Info
|
IC50 = 47 nM |
[1] |
Japan Patent Office (JPO) |
Patent ID |
JP2012176934 |
Title |
Heterocyclic Compounds As Iap (Inhibitors of Apoptosis Protein) Antagonists and Pharmaceuticals Containing Them. |
Representative Drug(s) |
D05HBW |
Drug Info
|
99% inhibition = 3000 nM |
[1] |
Patent ID |
JP2012106958 |
Title |
Heterocyclic Compounds, Pharmaceuticals Containing Them, Method for Antagonizing Inhibitors of Apoptosis Proteins By The Compounds, and Prevention or Treatment of Cancer Using Them. |
Representative Drug(s) |
D0F4GT |
Drug Info
|
96% inhibition = 3000 nM |
[1] |